Navigation Links
Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Date:6/3/2009

Sees opportunity to end abusive use of authorized generics during period of exclusivity

PITTSBURGH, June 3 /PRNewswire-FirstCall/ -- Mylan Inc.'s (Nasdaq: MYL) Chief Operating Officer Heather Bresch today testified before the U.S. House of Representatives Judiciary Subcommittee on Courts and Competition Policy concerning patent litigation settlements between branded pharmaceutical companies and generic pharmaceutical companies. During her testimony, Bresch conveyed Mylan's position that the launch of an authorized generic by brand companies during a generic company's 180-day exclusivity period undermines competition and delays timely access to high quality, affordable generic medications for patients, taxpayers, the government and businesses.

The committee's hearing, "Pay to Delay: Are Patent Settlements That Delay Generic Drug Market Entry Anticompetitive?," was called to gather information about the effects of settlements.

Bresch commented: "When it comes to settlements, Congress need look no further than the use and abuse of authorized generics by brand manufacturers. The increase in the number of patent litigation settlements in recent years is directly related to the increased use of authorized generics during the 180-day market exclusivity period. This tactic upsets the natural balance of incentives that Congress intended with its 1984 Hatch-Waxman legislation."

Bresch continued: "Congress has an opportunity to act now to ensure that timely access to affordable generics is offered to patients by restoring the true 180-day exclusivity period. This is even more profound and critical today as Congress deliberates on a regulatory pathway for life-saving generic biologics, treatments that can cost hundreds of thousands of dollars per patient per year."

A complete version o
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
2. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
3. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
4. Mylan Confirms Four First-to-File Challenges
5. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
6. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
7. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Synedgen Inc. is pleased to announce ... Manager. , Dr. Nguyen brings to Synedgen critical regulatory ... company as it moves forward in the FDA regulatory ... two years. Dr. Nguyen will lead the management of ... documents that must be completed in order to initiate ...
(Date:5/4/2015)... 4, 2015 Tobira Therapeutics, Inc. (NASDAQ: ... development and commercialization of novel treatments for liver ... its merger with Regado Biosciences, Inc. (NASDAQ: RGDO, ... of the merger, Tobira raised $40 million of ... and all current Tobira institutional investors, including the ...
(Date:5/4/2015)... 2015 GliaCure, a privately-held biotechnology company ... neurological and neuropsychiatric disorders based on glial targets, ... patients in a Phase 1b clinical trial of ... as a potential disease-modifying treatment. GliaCure,s innovative approach ... it both promotes the clearance of amyloid and ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ - ... pleased to announce the appointment of Dr. Roger ... extensive experience guiding biotech companies in matters including ... Fluorinov,s leadership team and adds significant regulatory expertise ... Dr. Garceau brings 30 years of pharmaceutical ...
Breaking Biology Technology:Synedgen Announces the Appointment of Regulatory Affairs Manager 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... electrical properties, carbon nanotubes are attractive building ... sensors, logic devices, and memory elements. ... arrays of individual carbon nanotubes and the ... large-scale commercial use. Now, researchers at ...
... 7, 2010 Naurex Inc., a clinical-stage company developing ... neurology, reported that data being presented today at the ... (ACNP) further confirm that its lead antidepressant candidate GLYX-13 ... that have limited the clinical utility of other NMDA ...
... completely, it would be more than six feet long. It,s hard ... your cells, but that,s exactly how it works. For ... DNA is packaged in cells, and have found strong indications that the ... mostly of an amino acid molecule called a histone influences the ...
Cached Biology Technology:Using new materials to make more reliable nanoelectromechanical systems 2New Preclinical Data Confirm Naurex's Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine 2New Preclinical Data Confirm Naurex's Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine 3New Preclinical Data Confirm Naurex's Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine 4UNC-led team tests commonly used antibodies 2
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... release is available in Spanish . , ... processes, but also those that do not. This is why ... healthy cells. With this aim in mind, a team from ... of the C1P molecule. Today two types of ...
... N.Y. New tires allow race cars to take tight ... similar advantages: They are not necessary for basic flight but ... "To escape a predator, you don,t have to be fast, ... a world authority on animal behavior, ecology and evolution and ...
... pollution has already spurred public health officials to advise eating ... in a warmer world. So suggests a paper that ... . Sue Natali, a postdoctoral associate in botany at ... mercury levels in soils under trees growing in air enriched ...
Cached Biology News:The quest for specific anti-inflammatory treatment 2The quest for specific anti-inflammatory treatment 3Hind wings help butterflies make swift turns to evade predators, study finds 2To climate-change worries, add 1 more: Extended mercury threat 2To climate-change worries, add 1 more: Extended mercury threat 3
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
...
... to Sf-900 II SFM.Sf21 ... from Spodoptera frugiperda (Fall ... (1). The Sf21 cells ... suspension culture in Sf-900 ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Biology Products: